Altimmune Inc (NASDAQ:ALT) had an increase of 23.51% in short interest. ALT’s SI was 975,500 shares in June as released by FINRA. Its up 23.51% from 789,800 shares previously. With 363,200 avg volume, 3 days are for Altimmune Inc (NASDAQ:ALT)’s short sellers to cover ALT’s short positions. The SI to Altimmune Inc’s float is 11.07%. The stock increased 7.45% or $0.0386 during the last trading session, reaching $0.5566. About 887,256 shares traded or 7.85% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 88.88% since June 18, 2017 and is downtrending. It has underperformed by 101.45% the S&P500. Some Historical ALT News: ; 27/03/2018 – ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATIT…; 28/03/2018 – ALTIMMUNE – AT DECEMBER 31, 2017, HAD CASH, CASH EQUIVALENTS, AND RESTRICTED CASH OF APPROXIMATELY $12.3 MLN; 27/03/2018 – Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX lntranasal lnfluenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection; 27/03/2018 – ALTIMMUNE INC – HEPTCELL VACCINE WAS WELL TOLERATED BUT T-CELL IMMUNOGENICITY RESULTS WERE INCONCLUSIVE; 12/03/2018 – Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program; 26/03/2018 – Tauriga Sciences, Inc. Elects to Change the Name of its Recently Formed Delaware Subsidiary to: Tauriga Biz Dev Corp; 27/03/2018 – ALTIMMUNE – RESULTS FROM NASOVAX INTRANASAL FLU VACCINE PHASE 2A STUDY IN 60 HEALTHY INDIVIDUALS SHOWED 100% SEROPROTECTION IN MID- & HIGH-DOSE GROUPS; 20/03/2018 – Altimmune to Announce Year End 2017 Financial Results on March 29; 28/03/2018 – Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update; 27/03/2018 – ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC…
Empirical Financial Services Llc increased Boeing Co (BA) stake by 48.91% reported in 2018Q1 SEC filing. Empirical Financial Services Llc acquired 1,824 shares as Boeing Co (BA)’s stock declined 0.93%. The Empirical Financial Services Llc holds 5,553 shares with $1.70M value, up from 3,729 last quarter. Boeing Co now has $206.81 billion valuation. The stock decreased 0.81% or $2.89 during the last trading session, reaching $354.99. About 2.43 million shares traded. The Boeing Company (NYSE:BA) has risen 92.49% since June 18, 2017 and is uptrending. It has outperformed by 79.92% the S&P500. Some Historical BA News: ; 25/04/2018 – BOEING CEO SAYS MARKET OUTLOOK PROVIDES SOLID FOUNDATION FOR PLANNED PRODUCTION RATES – CONF CALL; 07/03/2018 – General Motors and Boeing declined 1.3 percent and 1.4 percent, respectively. United Technologies and Ford Motor slipped 1.1 percent and 0.9 percent, respectively; 06/03/2018 – Hawaiian Airlines Signs Letter of Intent for Buying 10 Boeing 787-9 Dreamliner Aircraft; 25/04/2018 – Boeing Company: 1st Quarter Results; 26/04/2018 – Southwest Jet Order to Give Boeing its Biggest 737 Max Fleet; 25/04/2018 – BOEING SEES SPENDING $12B ON SHARE BUYBACKS OVER NEXT 2 YEARS; 05/04/2018 – China tariffs on U.S. business jets seen a boon for Canada’s Bombardier, others; 12/04/2018 – Boeing Joins Saab in Race for World’s Biggest Fighter Jet Deal; 17/04/2018 – SPIRIT COULD ORDER AIRBUS, BOMBARDIER, EMBRAER, BOEING PLANES; 08/05/2018 – Silver Air’s Boeing Business Jet Ready for Charter
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $12.39 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.
More notable recent The Boeing Company (NYSE:BA) news were published by: Seekingalpha.com which released: “$6 Billion Order Loss For Boeing?” on June 18, 2018, also Seekingalpha.com with their article: “Boeing’s Nightmare: Picking Fights With China” published on June 17, 2018, Seekingalpha.com published: “797 Announcement Will Increase Boeing Stock Price” on June 18, 2018. More interesting news about The Boeing Company (NYSE:BA) were released by: Seekingalpha.com and their article: “Boeing Optimizes Defense Products” published on June 15, 2018 as well as Seekingalpha.com‘s news article titled: “Boeing Books $4.2 Billion Worth Of Orders” with publication date: June 14, 2018.
Among 27 analysts covering Boeing (NYSE:BA), 19 have Buy rating, 1 Sell and 7 Hold. Therefore 70% are positive. Boeing had 118 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of The Boeing Company (NYSE:BA) earned “Neutral” rating by Buckingham Research on Thursday, February 8. On Wednesday, July 5 the stock rating was maintained by Jefferies with “Buy”. As per Friday, August 4, the company rating was maintained by UBS. RBC Capital Markets maintained it with “Hold” rating and $273.0 target in Thursday, October 26 report. Cowen & Co maintained the shares of BA in report on Friday, December 1 with “Buy” rating. On Wednesday, January 17 the stock rating was maintained by Seaport Global with “Buy”. The firm has “Hold” rating by Buckingham Research given on Friday, December 22. The stock has “Neutral” rating by Buckingham Research on Friday, July 28. On Wednesday, July 26 the stock rating was maintained by Canaccord Genuity with “Hold”. The rating was maintained by RBC Capital Markets with “Underperform” on Thursday, April 27.
Investors sentiment decreased to 0.66 in 2018 Q1. Its down 0.13, from 0.79 in 2017Q4. It turned negative, as 60 investors sold BA shares while 691 reduced holdings. 128 funds opened positions while 368 raised stakes. 360.90 million shares or 3.37% less from 373.50 million shares in 2017Q4 were reported. Bragg Financial Advsr Incorporated has 0.27% invested in The Boeing Company (NYSE:BA) for 5,560 shares. Raymond James Svcs Advisors Inc, Florida-based fund reported 177,127 shares. 18,007 were accumulated by D L Carlson Invest Gp Inc. Peloton Wealth Strategists owns 8,351 shares. Eaton Vance Management accumulated 1.22 million shares or 0.99% of the stock. Moreover, Excalibur Mgmt Corporation has 0.22% invested in The Boeing Company (NYSE:BA) for 815 shares. 56,805 were accumulated by Bridgeway Cap Management. Levy Harkins & Co reported 111,143 shares. Modera Wealth Mngmt Ltd Liability Co holds 2,486 shares. Fmr Limited Liability owns 6.39M shares. Finance Consulate Incorporated holds 0.13% in The Boeing Company (NYSE:BA) or 754 shares. Fin Advisory Gp owns 0.39% invested in The Boeing Company (NYSE:BA) for 3,983 shares. Ruggie Capital Gru holds 0.04% or 242 shares in its portfolio. Vnbtrust National Association holds 0.43% or 2,262 shares in its portfolio. Hodges Cap Inc reported 26,346 shares stake.
Since February 8, 2018, it had 0 insider buys, and 6 insider sales for $18.83 million activity. CAPOZZI HEIDI B had sold 1,132 shares worth $373,379 on Thursday, May 3. Another trade for 9,000 shares valued at $3.10M was made by LUTTIG J MICHAEL on Wednesday, May 9. Sands Diana L also sold $1.48M worth of The Boeing Company (NYSE:BA) on Friday, May 4. Smith Gregory D had sold 36,079 shares worth $12.17 million on Thursday, February 8. 2,840 shares valued at $948,261 were sold by Verbeck Robert E on Friday, May 4. 2,241 shares were sold by Hyslop Gregory L, worth $762,543.